BerGenBio, an emerging oncology biopharma, today announced the appointment of Dr Sue Foden to its Board of Directors. Foden was one of the founders of Cancer Research UK and also served as CEO of both Cancer Research Campaign Technology Ltd and Cancer Research Ventures Ltd. She was also an investment director at Merlin Biosciences, advisor on several EU projects and currently holds a range of directorships including Source (News – Alert) Bioscience plc, Elara GmbH and Vectura plc. Following a recent successful fundraising led by Sarsia Seed, Foden’s appointment represents a further strengthening of the company as it gears up to taking its lead programme BGB324, a first in class AXL inhibitor, into Phase I trials in 2012.
Richard Godfrey, BerGenBio’s CEO, welcomed Foden’s appointent: “Sue brings to BerGenBio both a wealth of experience in oncology pipeline development and a wide network of commercial contacts. We hope to utilize both as we bring BGB324, our proprietary AXL inhibitor, to clinic next year and also broaden our portfolio of other novel oncology targets based around EMT in particular.
Dr Foden added: “The quality of the science and the strength of the team initially attracted me to BerGenBio. I also see a real breadth of commercialisation opportunities and the possibility to build an attractive pipeline for investors over the next few years.”
Notes to editors
BerGenBio AS is a biopharmaceutical company located in Bergen, Norway and founded on proprietary platform technology called CellSelect™. The CellSelect technology uses information from RNAi screening studies to identify novel drug targets involved in disease. BerGenBio has a deep understanding of Cancer biology and in particular the tumor micro-environment, EMT and mechanisms of drug resistance. Having generated significant fee for service revenues with CellSelect, BerGenBio AS is now transitioning to developing first in class oncology therapeutics through to Phase II.
Richard Godfrey, CEO